
Global Graft Versus Host Disease Market Growth, Size, Trends Analysis- By Disease Type, By Treatment Type, By Age Group, Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
Graft Versus Host Disease Market Introduction and Overview
According to SPER market research, ‘Global Graft Versus Host Disease Market Size- By Disease Type, By Treatment Type, By Age Group, Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Graft Versus Host Disease Market is predicted to reach 6.84 Billion by 2034 with a CAGR 8.46%.
Graft Versus Host Disease (GVHD) is a complication that can arise after a bone marrow or stem cell transplant, where the donated immune cells (the graft) attack the recipient’s body (the host). This happens because the donor’s immune system identifies the recipient’s tissues as foreign and launches an immune response. GVHD can affect various organs, most commonly the skin, liver, and gastrointestinal tract, leading to symptoms such as skin rashes, liver issues, and digestive problems like diarrhea and stomach pain.
Restraints:
The graft versus host disease (GVHD) treatment market encounters several significant challenges that impact its growth. The disease’s complexity and variability in patient response make it difficult to establish standardized treatment protocols. A major hurdle is the limited availability of perfectly matched donors, which raises the risk of GVHD following transplants. Existing therapies often depend on immunosuppressants, which can cause severe side effects and weaken the immune system.
Global Graft Versus Host Disease Market Segmentation:
By Disease Type: Based on the Disease Type, Global Graft Versus Host Disease Market is segmented as; Acute graft versus host disease (aGVHD), Chronic graft versus host disease (cGVHD
By Treatment Type: Based on the Treatment Type, Global Graft Versus Host Disease Market is segmented as; Monoclonal antibodies, mTOR inhibitors, Tyrosine kinase inhibitors, Immunosuppressants, Corticosteroids, Other treatment types.
By Age Group: Based on the Age Group, Global Graft Versus Host Disease Market is segmented as; 20 years, 21-50 years, 51 years and above.
By Route of Administration: Based on the Route of Administration, Global Graft Versus Host Disease Market is segmented as; Oral, Intravenous, Topical.
By Distribution Channel: Based on the Distribution Channel, Global Graft Versus Host Disease Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.
According to SPER market research, ‘Global Graft Versus Host Disease Market Size- By Disease Type, By Treatment Type, By Age Group, Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Graft Versus Host Disease Market is predicted to reach 6.84 Billion by 2034 with a CAGR 8.46%.
Graft Versus Host Disease (GVHD) is a complication that can arise after a bone marrow or stem cell transplant, where the donated immune cells (the graft) attack the recipient’s body (the host). This happens because the donor’s immune system identifies the recipient’s tissues as foreign and launches an immune response. GVHD can affect various organs, most commonly the skin, liver, and gastrointestinal tract, leading to symptoms such as skin rashes, liver issues, and digestive problems like diarrhea and stomach pain.
Restraints:
The graft versus host disease (GVHD) treatment market encounters several significant challenges that impact its growth. The disease’s complexity and variability in patient response make it difficult to establish standardized treatment protocols. A major hurdle is the limited availability of perfectly matched donors, which raises the risk of GVHD following transplants. Existing therapies often depend on immunosuppressants, which can cause severe side effects and weaken the immune system.
Global Graft Versus Host Disease Market Segmentation:
By Disease Type: Based on the Disease Type, Global Graft Versus Host Disease Market is segmented as; Acute graft versus host disease (aGVHD), Chronic graft versus host disease (cGVHD
By Treatment Type: Based on the Treatment Type, Global Graft Versus Host Disease Market is segmented as; Monoclonal antibodies, mTOR inhibitors, Tyrosine kinase inhibitors, Immunosuppressants, Corticosteroids, Other treatment types.
By Age Group: Based on the Age Group, Global Graft Versus Host Disease Market is segmented as; 20 years, 21-50 years, 51 years and above.
By Route of Administration: Based on the Route of Administration, Global Graft Versus Host Disease Market is segmented as; Oral, Intravenous, Topical.
By Distribution Channel: Based on the Distribution Channel, Global Graft Versus Host Disease Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.
By Region:
This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.
Table of Contents
244 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER’s Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Graft Versus Host Disease Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Graft Versus Host Disease Market
- 7. Global Graft Versus Host Disease Market, By Disease Type, (USD Million) 2021-2034
- 7.1. Acute graft versus host disease (aGVHD)
- 7.2. Chronic graft versus host disease (cGVHD)
- 8. Global Graft Versus Host Disease Market, By Treatment Type, (USD Million) 2021-2034
- 8.1. Monoclonal antibodies
- 8.2. mTOR inhibitors
- 8.3. Tyrosine kinase inhibitors
- 8.4. Immunosuppressants
- 8.5. Corticosteroids
- 8.6. Other treatment types
- 9. Global Graft Versus Host Disease Market, By Age Group, (USD Million) 2021-2034
- 9.1.20 years
- 9.2.21-50 years
- 9.3.51 years and above
- 10. Global Graft Versus Host Disease Market, By Route of Administration, (USD Million) 2021-2034
- 10.1. Oral
- 10.2. Intravenous
- 10.3. Topical
- 11. Global Graft Versus Host Disease Market, By Distribution Channel, (USD Million) 2021-2034
- 11.1. Hospital pharmacies
- 11.2. Retail pharmacies
- 11.3. Online pharmacies
- 12. Global Graft Versus Host Disease Market, (USD Million) 2021-2034
- 12.1. Global Graft Versus Host Disease Market Size and Market Share
- 13. Global Graft Versus Host Disease Market, By Region, 2021-2034 (USD Million)
- 13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
- 13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
- 13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
- 13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
- 13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America
- 14. Company Profile
- 14.1. Astellas Pharma Inc.
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
- 14.2. Bristol Myers Squibb
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
- 14.3. ElsaLys Biotech SA
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
- 14.4. Incyte Corporation
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
- 14.5. Johnson & Johnson Services, Inc.
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
- 14.6. Kiadis Pharma
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
- 14.7. Mallinckrodt Pharmaceuticals
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
- 14.8. Merck & Co., Inc.
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
- 14.9. Mesoblast Ltd.
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
- 14.10. Neovii Pharmaceuticals AG
- 14.10.1. Company details
- 14.10.2. Financial outlook
- 14.10.3. Product summary
- 14.10.4. Recent developments
- 14.11. Novartis AG
- 14.11.1. Company details
- 14.11.2. Financial outlook
- 14.11.3. Product summary
- 14.11.4. Recent developments
- 14.12. Pfizer Inc.
- 14.12.1. Company details
- 14.12.2. Financial outlook
- 14.12.3. Product summary
- 14.12.4. Recent developments
- 14.13. Sanofi
- 14.13.1. Company details
- 14.13.2. Financial outlook
- 14.13.3. Product summary
- 14.13.4. Recent developments
- 14.14. Soligenix
- 14.14.1. Company details
- 14.14.2. Financial outlook
- 14.14.3. Product summary
- 14.14.4. Recent developments
- 14.15. Others
- 15. Conclusion
- 16. List of Abbreviations
- 17. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.